Axogen Inc (AXGN) Stock Price, Quote & News

Company Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral...

Industry: Medical Devices

Sector: Healthcare

Phone: 386 462 6800

Fax: 386 462 6801

Website: www.axogeninc.com

Address:

13631 Progress Boulevard, Suite 400, Alachua, United States

LuckEtradER Oct. 25 at 1:00 AM

$AXGN so bullish here next 60 days

0 · Reply

Titleist123 Oct. 24 at 5:16 PM

$AXGN what does FDA approval bring us to- $25/30?

1 · Reply

LuckEtradER Oct. 22 at 9:31 PM

$AXGN cup and handle on the 6 month? Ties in nicely to Dec 5th decision looming 👀

1 · Reply

dustin1101 Oct. 21 at 2:28 PM

$AXGN $18’s on the way again it looks.

0 · Reply

PremarketAnalysis Oct. 19 at 1:34 AM

$AXGN SignalEngine: MM Infl (Bullish) (1h bias), Algo Vol 45%, Org Vol 55%, Res 17.08, Sup 15.48 Algo Int: Spoofing tape to stall action.. synthetic rotation developing within profit zone. Momentum Feed: https://premarketanalysis.com/#momentum=AXGN

0 · Reply

Biobrocker12 Oct. 16 at 9:09 AM

$AXGN free fda approval research https://docs.google.com/document/d/14-EwuIcWXfDa2wHZj_NlXykbXc4_D7m3Gmt36zRvHfA/edit?usp=drivesdk

1 · Reply

LuckEtradER Oct. 16 at 12:21 AM

$AXGN 12/5

0 · Reply

BrennadPurdysw Oct. 12 at 5:47 PM

CVKD Exciting news: Cadrenal Therapeutics Company Webcast @ Lytham Partners Fall 2025 Investor Conference. Watch live here: https://youtu.be/NfPbBjgeIbg?si=2xPvJ2_YJQjHipGa $CVM $TARS $AROC $AXGN $RGR

0 · Reply

BioTechHealthX Oct. 12 at 5:07 PM

$AXGN Revenue jumped 17.4% year-over-year as Axogen nears its FDA BLA decision. Analysts project up to 60% upside before the December 5 ruling. https://biotechhealthx.com/biotech-news/axogen-axgn-surges-toward-26-target-as-nerve-repair-demand-soars-17/

0 · Reply

Tain0os Oct. 10 at 8:38 PM

$SPY $CSPX (Ireland S&P 500) firm long at the EU open tomorrow. Opened Q4 net longs today -> $RGNX $OMER $INVA $AXGN

1 · Reply

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Oct 1, 2025, 10:50 AM EDT - 24 days ago

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Aug 25, 2025, 6:40 AM EDT - 2 months ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 12, 2025, 5:17 AM EDT - 2 months ago

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Aug 5, 2025, 1:15 PM EDT - 2 months ago

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 4:10 PM EDT - 3 months ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 22, 2025, 4:05 PM EDT - 3 months ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

May 28, 2025, 8:00 AM EDT - 5 months ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 9, 2025, 3:21 PM EDT - 6 months ago

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:05 AM EDT - 6 months ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Apr 24, 2025, 8:04 AM EDT - 6 months ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Feb 25, 2025, 1:58 PM EST - 8 months ago

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:10 AM EST - 8 months ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 11, 2025, 4:58 PM EST - 9 months ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Jan 10, 2025, 5:00 PM EST - 10 months ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2025, 8:01 PM EST - 10 months ago

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Nov 9, 2024, 9:53 AM EST - 1 year ago

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Aug 8, 2024, 2:10 PM EDT - 1 year ago

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Axogen, Inc. Announces New Leadership Appointments

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 1, 2024, 7:00 AM EDT - 1 year ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

May 28, 2024, 4:30 PM EDT - 1 year ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 5, 2024, 1:21 AM EDT - 1 year ago

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:50 PM EDT - 1 year ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Mar 5, 2024, 11:03 AM EST - 1 year ago

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 1 year ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Feb 13, 2024, 4:30 PM EST - 1 year ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 2, 2024, 4:15 PM EST - 1 year ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jan 18, 2024, 5:00 PM EST - 1 year ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 4, 2024, 4:45 PM EST - 1 year ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:40 PM EST - 1 year ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:35 PM EST - 1 year ago

Axogen Announces Promotions on Research and Development Team

Dec 26, 2023, 4:15 PM EST - 1 year ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 6, 2023, 7:00 AM EST - 2 years ago

Axogen Announces Transition of Finance Team Leadership

Dec 1, 2023, 5:00 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023, 9:49 AM EST - 2 years ago

AxoGen, Inc. (AXGN) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:00 AM EST - 2 years ago

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Oct 18, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

Aug 31, 2023, 7:00 AM EDT - 2 years ago

Axogen to Participate at Upcoming Investor Conferences

Aug 21, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

Aug 7, 2023, 9:34 PM EDT - 2 years ago

AxoGen, Inc. (AXGN) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 4:01 PM EDT - 2 years ago

Axogen, Inc. Reports 2023 Second Quarter Financial Results

Jul 27, 2023, 7:00 AM EDT - 2 years ago

Axogen to Participate at Canaccord Genuity's 43rd Annual Growth Conference

LuckEtradER Oct. 25 at 1:00 AM

$AXGN so bullish here next 60 days

0 · Reply

Titleist123 Oct. 24 at 5:16 PM

$AXGN what does FDA approval bring us to- $25/30?

1 · Reply

LuckEtradER Oct. 22 at 9:31 PM

$AXGN cup and handle on the 6 month? Ties in nicely to Dec 5th decision looming 👀

1 · Reply

dustin1101 Oct. 21 at 2:28 PM

$AXGN $18’s on the way again it looks.

0 · Reply

PremarketAnalysis Oct. 19 at 1:34 AM

0 · Reply

Biobrocker12 Oct. 16 at 9:09 AM

$AXGN free fda approval research https://docs.google.com/document/d/14-EwuIcWXfDa2wHZj_NlXykbXc4_D7m3Gmt36zRvHfA/edit?usp=drivesdk

1 · Reply

LuckEtradER Oct. 16 at 12:21 AM

$AXGN 12/5

0 · Reply

BrennadPurdysw Oct. 12 at 5:47 PM

0 · Reply

BioTechHealthX Oct. 12 at 5:07 PM

0 · Reply

Tain0os Oct. 10 at 8:38 PM

$SPY $CSPX (Ireland S&P 500) firm long at the EU open tomorrow. Opened Q4 net longs today -> $RGNX $OMER $INVA $AXGN

1 · Reply

Tain0os Oct. 10 at 8:33 PM

$AXGN started with a small long position in the low intraday

0 · Reply

LuckEtradER Oct. 9 at 10:08 PM

$AXGN good op w/ pending approval early December IMO

0 · Reply

BEATOFtheMARKET Oct. 9 at 4:03 PM

Results of list 9/26/25 $AXGN $AXL $AXP Cycle Trading Signal plugged into AI 🔥

0 · Reply

dustin1101 Oct. 7 at 1:40 PM

$AXGN Adding shares back again.

0 · Reply

kgnfdeagle Oct. 3 at 4:30 PM

$AXGN Long from $18.00 -- Zacks Homerun pick.

1 · Reply

Quantumup Oct. 2 at 11:05 AM

Canaccord Genuity yesterday reiterated $AXGN at a Buy rating and a $24 price target. $XBI $IBB Canaccord Genuity today reiterated AxoGen, Inc. (AXGN) at a Buy rating and $24 price target. Canaccord Genuity's note from y'day also answers some questions y'all may have on the Shutdown in regards to the HHS/FDA and what in means to the Healthcare Industry. Canaccord Genuity said in its notes to investors:

0 · Reply

LuckEtradER Oct. 1 at 11:36 PM

$AXGN

0 · Reply

dustin1101 Oct. 1 at 2:31 PM

$AXGN Weak handed buyers from yesterday’s H.C. W coverage are discovering this is a thin stock and they’re pounding out with 70K total volume traded.. this will turn back up IMO. Amateur hour.

1 · Reply

JarvisFlow Sep. 30 at 10:56 AM

HC Wainwright & Co. updates rating for Axogen ( $AXGN ) to Buy, target set at 25.

0 · Reply

healthcareguru Sep. 30 at 2:04 AM

Healthcare M&A Takeout / Must-Own Basket: $AXGN $AVTR $ADMA $EVH $SGRY 🔥💪👍💵

1 · Reply

GFstocktwits Sep. 29 at 12:46 PM

$AXGN why buy a "second runner", take a look at RNV on the asx when you feel like it

0 · Reply

dustin1101 Sep. 24 at 7:40 PM

$AXGN Just keep buying the dips.. Added back what I sold 17.65 at 17.10 today. Steady freight train momentum as buyers continue to slowly accumulate.

0 · Reply

Market Cap	830.54M
Revenue (ttm)	187.34M
Net Income (ttm)	-9.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5.32%
Debt to Equity Ratio	0.43

Volume	485,700
Avg Vol	951,628
Day's Range	N/A - N/A
Shares Out	46.01M
Stochastic %K	94%
Beta	1.04
Analysts	Strong Sell
Price Target	$24.75